3 / 27
Notes:
Page 44
Volume 09
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Epilepsy 2019
Parkinsons Congress 2019
August 29-31, 2019
JOINT EVENT
conferenceseries
.com
August 29-31, 2019 Vienna, Austria
&
5
th
International Conference on
Epilepsy & Treatment
5
th
World Congress on
Parkinsons & Huntington Disease
Vagus Nerve Stimulation (VNS) is an adjunctive treatment in Iraqi patients with drug resistant epilepsy
Anmar Hatem
Medical City, Iraq
Background:
Despite the introduction of new antiepileptic drugs (AEDs) and advances in the surgical treatment of
epilepsy, an important group of patients still remains uncontrolled by any of these methods. Vagus nerve stimulation
(VNS) is an adjunctive treatment for those with drug resistant epilepsy. In addition to the reduction in seizure
frequency, there is other variables need to be assessed for better determination of VNS efficacy like quality of life
(QOL) improvement.
Aims of the Study:
Evaluate the effectiveness of VNS, for Iraqi patients with drug resistant epilepsy, in reducing
seizure frequency and improving QOL of these patients.
Method and Patients:
Forty-six patients of drug resistant epilepsy were retrospectively examined. They underwent
implantation of a stimulator in Baghdad medical city during 2015, and with a follow-up of one year. They were 25
male and 21 females, and their ages at VNS implantation was ≥18 year old for 28 patients and between11-17 year
old for 18 patients. Analysis of seizure reduction (using McHugh classification) with the effect of demographic and
clinical variables on it, and assessment of QOL (using QOLIE-35 and QOLIE-AD 48 scales) were done in this study.
SSPS v.22 was used for the statistical analysis.
Results:
The total well response rate (including class I and II and equal to reduction in seizure frequency ≥ 50%)
was 58.7 % (27/46 patients), 6 cases became seizure free, and 6 cases reported no improvement, we also found that
the factors of gender, age and predominant seizure type had clinical outcome effects. The mean seizure frequency
and number of AEDs that used by the patients reduced. The mean of all domains and overall score of QOL scales
improved and some domains had statistically significant improvement.
Conclusion:
VNS is a safe, well-tolerated and effective treatment in reducing seizure frequency and improving QOL
for patients with drug resistant epilepsy.
Biography
Anmar Hatem is a board-certified and experienced consultant neurologist providing patients at Neurology sector of Baghdad Teaching Hospital care for a wide
range of conditions. He joined Neurological Specialties in 2005 with a special expertise in the field of Epilepsy, Multiple Sclerosis, and botulinum toxin therapy. He
graduated from Medical College at the University of Basra and completed his internship and neurology residency at Baghdad Teaching Hospital .He continued
his training and got The Board degree at the Iraqi Board of medical specialization in neurology. Now Dr Anmar is Secretory general for Iraqi neurology society
since 2017 and a trainer in both Iraqi board of neurology and Arabian board of medicine.
Anmar Hatem, J Alzheimers Dis Parkinsonism 2019, Volume 09